Quoin Pharmaceuticals Ltd
Change company Symbol lookup
Select an option...
QNRX Quoin Pharmaceuticals Ltd
SPUU.NV Direxion Daily S&P 500 Bull 2X Shares
NEOV NeoVolta Inc
SYBX Synlogic Inc
FIISO Financial Institutions Inc
KA Kineta Inc
TCS Container Store Group Inc
MLGO MicroAlgo Inc
INDI indie Semiconductor Inc
JCI Johnson Controls International PLC

Health Care : Biotechnology |
Based in Israel
Company profile

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
Day's Change
-0.30 (-6.00%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Morgan Stanley's stock has underperformed the market since James Gorman became CEO in 2010

10:42 am ET May 19, 2023 (MarketWatch)

By Tomi Kilgore

Morgan Stanley's stock has more than tripled in value since Gorman took over in January 2010, while the S&P 500 has nearly quadrupled

Shares of Morgan Stanley took a hit Friday, but perhaps shareholders shouldn't be too concerned over news of the planned departure of the investment bank's longtime chief executive, James Gorman.

At Morgan Stanley's annual general shareholder meeting on Friday, Gorman said he planned to step down sometime in the next 12 months, in the absence of a major change in the macroeconomic environment. That sent the stock (MS) down 0.6% in morning trading to buck a rally in the financial sector and the broader stock market.

Gorman became CEO of Morgan Stanley in January 2010, at the end of the 2008-09 financial crisis.

The stock has run up 215.5% since the end of January 2010, when it closed at $26.78, through Thursday's closing price of $84.49.

That outperformed the 184.5% gain for the Financial Select Sector SPDR exchange-traded fund (XLF) over the same time but underperformed the S&P 500's rally of 290.9%.

The stock also underperformed shares of JPMorgan Chase & Co. (JPM), which have climbed 258.2% during that time. Jaime Dimon has been CEO of JPMorgan Chase since Jan. 1, 2006. Since the end of 2005, JPMorgan's stock has gone up 251.5% with Dimon as CEO, while Morgan Stanley's stock has advanced 79.4% and the S&P 500 has climbed 236.3%.

During Gorman's tenure, Morgan Stanley has outperformed Goldman Sachs Group Inc. (GS), with Goldman's stock gaining 121.6% since the end of January 2010.

And since the end of October 2018, when current Goldman CEO David Solomon took the reins, Morgan Stanley's stock has run up 85%, while Goldman shares have gained 46.2%.

-Tomi Kilgore

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

May 19, 2023 10:42 ET (14:42 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.